Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

4.23
-0.2200-4.94%
Post-market: 4.230.00000.00%18:27 EDT
Volume:241.61K
Turnover:1.04M
Market Cap:239.12M
PE:-3.53
High:4.51
Open:4.45
Low:4.16
Close:4.45
52wk High:9.70
52wk Low:2.94
Shares:56.53M
Float Shares:26.76M
Volume Ratio:0.66
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1995
EPS(LYR):-1.5778
ROE:-470.38%
ROA:-20.70%
PB:-3.12
PE(LYR):-2.68

Loading ...

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader Program Targeting Cancer at TPD Summit

Reuters
·
Oct 16

Foghorn Therapeutics Announces Significant Progress for Selective Arid1b Degrader at the 8TH Annual Tpd and Induced Proximity Summit

THOMSON REUTERS
·
Oct 16

Foghorn Therapeutics transferred with Buy rating at B. Riley

TIPRANKS
·
Sep 17

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire
·
Aug 27

Foghorn Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 06

Foghorn Therapeutics Q2 collaboration revenue rises, loss narrows

Reuters
·
Aug 05

Foghorn Therapeutics Inc - Selective Cbp Degrader on Track for Ind Studies in 2026

THOMSON REUTERS
·
Aug 05

Foghorn Therapeutics Inc - Has $198.7 Mln Cash, Runway Into 2028

THOMSON REUTERS
·
Aug 05

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

GlobeNewswire
·
Aug 05

Foghorn Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Aug 04

Foghorn Therapeutics Signs Major Lease Agreement for New Watertown Headquarters

Reuters
·
Jul 02

Foghorn Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 18

Foghorn Therapeutics Inc. to Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025

Reuters
·
May 22

Foghorn Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Foghorn Therapeutics Reports Strong Cash Position with $220.6 Million, Ensures Cash Runway into 2027; No Specific Sales or EPS Data Disclosed

Reuters
·
May 14

BRIEF-Foghorn Therapeutics Q1 EPS USD -0.3

Reuters
·
May 14

Press Release: Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

Dow Jones
·
May 14

North American Morning Briefing: Stock Futures Surge on China Deal

Dow Jones
·
May 12

North American Morning Briefing: Stock Futures Down As Oil Plunges

Dow Jones
·
May 05

Foghorn Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Neil Gallagher

Reuters
·
May 03